What are the risks of aHUS?

People with aHUS are at constant risk of sudden, catastrophic, and life-threatening symptoms and complications.1,2 As the disease continues to damage small blood vessels, vital organs can fail to work, either suddenly or over time.3-6

Here are some key facts about aHUS:

  • aHUS damages the kidneys. The kidneys’ job is to clean toxins from the blood and eliminate them through the urine. Many people will need long-term dialysis or kidney transplant if their kidneys stop working1,7,8
  • Almost half (46%) of patients experience pulmonary symptoms31
  • Extremely high blood pressure and edema (swelling) are other complications4,6,9
  • Almost half (48%) of patients experience neurological (brain and nervous system) symptoms2,10,11
  • About 4 out of 10 patients (43%) of patients have cardiovascular (heart and circulation) problems4,10
  • Almost one-third (30%) have diarrhea and other problems linked to the digestive system2,3,6

Want to know more?

Create your own Doctor Discussion Guide
Manage your disease with the aHUS Patient Symptom Tracker

1. Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10(suppl 17):1-12. 2. Legendre CM, Licht C, Muus P, et al. N Engl J Med. 2013;368:2169-2181. 3. Sellier-Leclerc A-L, Frémeaux-Bacchi V, Dragon-Durey MA, et al; French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392-2400. 4. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8:622-633. 5. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859. 6. Caprioli J, Noris M, Brioschi S, et al; for the International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279. 7. Sarode R, Bandarenko N, Brecher ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2013; DOI: 10.1002/jca.21302. [Epub ahead of print]. 8. Cofiell R, Kukreja A, Bedard K, et al. Poster presented at the 55th Annual Meeting of the American Society of Hematology; December 7-10, 2013; New Orleans, LA. Abstract 2184. 9. Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. 10. Heinen S, Pluthero FG, van Eimeren VF, et al. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol. 2013;54:84-88. 11. Boogaerts MA, Roelant C, Goosens W, et al. Complement activation and adult respiratory distress during intermittent flow apheresis procedures. Transfusion. 1986;26:82-87. 31. Muus P, Loirat C, Licht C, et al. Presented at: 18th Congress of the European Hematology Association. June 13-16, 2013; Stockholm, Sweden. Abstract B1774.